From Substrate to Fragments to Inhibitor Active
Adenine
/ chemistry
Animals
Anti-Bacterial Agents
/ pharmacology
Binding Sites
Cell Line
Crystallography, X-Ray
Female
Humans
Methicillin-Resistant Staphylococcus aureus
/ drug effects
Mice
Mice, Inbred BALB C
Microbial Sensitivity Tests
Phosphotransferases (Alcohol Group Acceptor)
/ antagonists & inhibitors
Small Molecule Libraries
Staphylococcal Infections
/ drug therapy
Staphylococcus aureus
/ drug effects
Structure-Activity Relationship
MRSA
adenosine derivative
antibacterial compound
bacterial NAD kinase
staphylococci
Journal
ACS infectious diseases
ISSN: 2373-8227
Titre abrégé: ACS Infect Dis
Pays: United States
ID NLM: 101654580
Informations de publication
Date de publication:
13 03 2020
13 03 2020
Historique:
pubmed:
6
2
2020
medline:
28
1
2021
entrez:
5
2
2020
Statut:
ppublish
Résumé
Antibiotic resistance is a worldwide threat due to the decreasing supply of new antimicrobials. Novel targets and innovative strategies are urgently needed to generate pathbreaking drug compounds. NAD kinase (NADK) is essential for growth in most bacteria, as it supports critical metabolic pathways. Here, we report the discovery of a new class of antibacterials that targets bacterial NADK. We generated a series of small synthetic adenine derivatives to screen those harboring promising substituents in order to guide efficient fragment linking. This led to NKI1, a new lead compound inhibiting NADK that showed
Identifiants
pubmed: 32017533
doi: 10.1021/acsinfecdis.9b00368
doi:
Substances chimiques
Anti-Bacterial Agents
0
Small Molecule Libraries
0
Phosphotransferases (Alcohol Group Acceptor)
EC 2.7.1.-
NAD kinase
EC 2.7.1.23
Adenine
JAC85A2161
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM